BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)

This reads like noise, not a catalyst: a generic plaintiff-bar solicitation is usually a lead-generation event, not evidence of incremental financial liability. The only time these notices matter is when they latch onto a company already facing a revenue miss, restatement, or governance failure; then litigation becomes a second-order compression mechanism through multiple de-rating and tighter financing terms, especially in small caps with weak liquidity.

The market risk is asymmetric only for names that are already crowded longs or have binary disclosure risk in the next 30-60 days. In those cases, even a low-probability investigation can widen borrow, raise option IV, and force de-risking from quant and retail holders before any real legal cost is known. Absent a named issuer, the expected value is too low for a standalone trade.

Broader spillover is more relevant to D&O insurers and defense-law demand than to equities, but even there this kind of notice is too generic to move pricing. The contrarian view is that investors often overpay for “investigation” headlines; most never become material, and the signal is usually just that a stock already has other problems.